Sugi Predict

Sugi Predict / Compounds / SCHEMBL2392665

SCHEMBL2392665

SCHEMBL2392665

CC(=O)Oc1c(C)cc(C=O)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 1/20 0.55
▸ KDM4E B2RXH2 6/20 0.46
▸ GAA P10253 4/20 0.46
▸ HTT P42858 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ TP53 P04637 2/20 0.46
▸ FNTA P49354 1/20 0.44
▸ FNTB P49356 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ POLB P06746 1/20 0.40
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38
▸ TUBA4A P68366 1/20 0.38
▸ TUBB4B P68371 1/20 0.38
▸ TUBB3 Q13509 1/20 0.38
▸ TUBB2A Q13885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21993634 0.89 KDM4E (0.49) SRCKDM4EGAAHTTHSD17B10
SCHEMBL294264 0.89 FNTA (0.50) SRCKDM4EGAAHTTHSD17B10
SCHEMBL24110815 0.86 TUBB4A (0.52) SRCGAAHTTFNTAFNTB
SCHEMBL4629904 0.85 FNTA (0.47) SRCKDM4EGAAHTTHSD17B10
SCHEMBL8671926 0.82 KDM4E (0.45) SRCKDM4EGAAHTTHSD17B10
SCHEMBL28603355 0.81 SRC (0.51) SRCKDM4EGAAHTTHSD17B10
SCHEMBL2939004 0.80 FNTA (0.55) KDM4EGAAHTTHSD17B10MAPT
SCHEMBL3156904 0.79 KDM4E (0.52) KDM4EGAAHTTHSD17B10MAPT
SCHEMBL23559320 0.78 FNTA (0.43) SRCKDM4EGAAHTTHSD17B10
SCHEMBL21758942 0.78 SRC (0.49) SRCFNTAFNTBALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240084308-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2024-03-14 — — US disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 — — US disclosed
US-11306066-B2 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors MONASH UNIVERSITY (AU) 2022-04-19 — — US disclosed
US-20210340547-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2021-11-04 — — US disclosed
US-11078488-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2021-08-03 — — US disclosed
CN-107567445-B 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity 坎塞拉有限公司 2021-06-29 — — CN disclosed
US-20200362354-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2020-11-19 — — US disclosed
US-10787668-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2020-09-29 — — US disclosed
EP-3328384-B1 FIBROTIC TREATMENT UNIV MONASH (AU) 2020-07-29 — — EP disclosed
US-20190249179-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2019-08-15 — — US disclosed
US-RE42700-E1 Induction of apoptosis in cancer cells SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-09-13 — — US disclosed
US-7989554-B2 Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid ENZON PHARMACEUTICALS, INC. (US) 2011-08-02 — — US disclosed
EP-1632479-B1 Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives SCHERING CORP (US) 2011-01-12 — — EP disclosed
CN-100348569-C Induction of apoptosis in cancer cells BURNHAM INST (US) 2007-11-14 — — CN disclosed
US-20070173615-A1 High efficiency method of preparing polyalkylene oxide carboxylic acids BELROSE PHARMA INC. 2007-07-26 — — US disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 — — US disclosed
CN-1659130-A Induction of apoptosis in cancer cells BURNHAM INST (US) 2005-08-24 — — CN disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 — — EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 — — US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787668-B2 Fibrotic treatment ENPEP, IL4I1, LNPEP SRC 2706/4885KDM4E 1261/4885GAA 1458/4885
US-20210340547-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP SRC 3481/4885KDM4E 1936/4885GAA 320/4885
US-20200362354-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP SRC 3481/4885KDM4E 1936/4885GAA 320/4885
US-20190249179-A1 FIBROTIC TREATMENT ENPEP, IL4I1, LNPEP SRC 2706/4885KDM4E 1261/4885GAA 1458/4885
US-11306066-B2 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors IAPP, ENPEP, DNPEP SRC 2793/4885KDM4E 1470/4885GAA 61/4885
US-11834663-B2 Fibrotic treatment MMP1, ENPEP, RNPEP SRC 3481/4885KDM4E 1936/4885GAA 320/4885
US-11078488-B2 Fibrotic treatment MMP1, ENPEP, RNPEP SRC 3481/4885KDM4E 1936/4885GAA 320/4885
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 SRC 717/4885KDM4E 2860/4885GAA 2036/4885
US-20240084308-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP SRC 3481/4885KDM4E 1936/4885GAA 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.